CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Income Statement [Abstract]
Net revenues	$ 34,880	$ 13,053	$ 82,888
Cost of revenues	11,664	7,982	39,870
Impairment of field equipment			6,412
Gross profit	23,216	5,071	36,606
Operating costs and expenses:
Research, development and clinical trials	9,411	11,445	41,467
Sales and marketing	14,756	13,308	59,449
General and administrative	12,422	12,256	51,007
Total operating costs and expenses	36,589	37,009	151,923
Operating loss	(13,373)	(31,938)	(115,317)
Financial expenses, net	(2,446)	(549)	(6,147)
Loss before income tax expense	(15,819)	(32,487)	(121,464)
Income tax expense	2,226	2,950	10,381
Net loss	$ (18,045)	$ (35,437)	$ (131,845)
Basic and diluted net loss per ordinary share	$ (0.21)	$ (0.42)	$ (1.54)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	87,452,983	84,397,164	85,558,448